Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Elite Pharmaceuticals, Inc. (OTC: ELTP).

Full DD Report for ELTP

You must become a subscriber to view this report.


Recent News from (OTC: ELTP)

Opioid prescriptions dropped 12% in 2017
Opioid prescriptions dropped 12% in 2017, according to a report from the IQVIA Institute for Human Data Science. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Industries Limited, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: April, 26 2018 03:18
U.S. opioid prescriptions down 12% last year, largest drop in 25 years
According to IQVIA ( IQV -0.8% ), U.S. opioid prescriptions declined 12% in 2017, the largest annual drop in 25 years as doctors respond to the opioid crisis. More news on: IQVIA Holdings, Inc., Insys Therapeutics, Inc., Johnson & Johnson, Healthcare stocks news, News on ETFs, ...
Source: SeekingAlpha
Date: April, 19 2018 11:25
DEA aiming to collar production of opioids
The U.S. Drug Enforcement Administration (DEA) has unveiled plans to restrict the amount of opioids made by drug firms if it believes the medications are being diverted for illicit use. The proposed new rules were announced today in a speech by Attorney General Jeff Sessions. More news o...
Source: SeekingAlpha
Date: April, 17 2018 15:35
Sen. Sanders introduces bill to fine opioid makers for marketing practices
Reuters reports that U.S. Senator Bernie Sanders (I-VT) plans to introduce a bill today that would fine makers of opioid medications for deceptive marketing and implement harsh penalties for those found responsible for contributing to the drug epidemic. More news on: Insys Therapeutics, ...
Source: SeekingAlpha
Date: April, 17 2018 12:03
Trump to release opioid epidemic plan
President Trump is set to unveil his Initiative to Stop Opioid Abuse in New Hampshire, which will seek to cut opioid prescriptions by a third over the next three years, as well as the death penalty for high-intensity drug traffickers. More news on: Johnson & Johnson, Endo Internation...
Source: SeekingAlpha
Date: March, 19 2018 04:25
Opioid settlement talks hit roadblocks
Federal Judge Dan Polster's push for a quick resolution of hundreds of lawsuits filed against drugmakers and distributors over their alleged role in the opioid crisis has hit a roadblock. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Industries Limited,...
Source: SeekingAlpha
Date: March, 08 2018 03:17
New Research: Key Drivers of Growth for Bioheart and Elite Pharmaceuticals - Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Bioheart Inc. ( OTCQB: USRM ) and Elite Pharmaceuticals Inc. ( OTCQB: ELTP ), including recent technical analysis and consolidated fundamental information. ...
Source: ACCESSWIRE IA
Date: March, 07 2018 07:30
Opioid overdoses spiked 30% in a year
Opioid overdoses spiked 30% between July 2016 and September 2017, according to a report from the Centers for Disease Control and Prevention. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Industries Limited, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: March, 07 2018 03:53
DOJ cracks down on opioid companies
Attorney General Jeff Sessions is cracking down on pharmaceutical companies that have contributed to the nation's opioid crisis. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Industries Limited, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: February, 28 2018 04:28
Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q3 2018 Results - Earnings Call Transcript
Elite Pharmaceuticals, Inc. (ELTP) Q3 2018 Earnings Conference Call February 12, 2018 11:30 AM ET Executives Nasrat Hakim - President and Chief Executive Officer Carter Ward - Chief Financial Officer Kenneth Smith - Vice President, Legal Presentation Operator Good morni...
Source: SeekingAlpha
Date: February, 12 2018 15:57

 


About Elite Pharmaceuticals, Inc. (OTC: ELTP)

Logo for Elite Pharmaceuticals, Inc. (OTC: ELTP)

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse deterrent opioid products as well as niche generic products. Elite specializes in oral sustained and controlled release drug products which have high barriers to entry. Elite owns generic and OTC products which have been licensed to TAGI Pharma, Epic Pharma, Dr. Reddy s Laboratories and Valeant Pharmaceuticals International. Elite currently has nine commercial products being sold, four products under review pending approval by the FDA, additional approved products pending manufacturing site transfer and the NDA filing for SequestOx . Elite s lead pipeline products include abuse deterrent opioids which utilize the Company s patented proprietary technology and a once daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain. These formulations are intended to address two major limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential opioid abuse. Elite also provides contract manufacturing for Ascend Laboratories a subsidiary of Alkem Laboratories Ltd. . Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. Learn more at www.elitepharma.com.

 

Contact Information

 

 

Current Management

  • Nasrat Hakim / CEO, President, Other
    • Mr. Hakim has more than years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, indepth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. From , Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing sites with more than , employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In , Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.Mr. Hakim s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs RAC from California State University at Sacramento, Sacramento, CA Bachelor in Chemistry/BioChemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.
  • Carter J. Ward / CFO, Secretary, Treasurer
    • Carter Ward joined Elite in July of as Chief Financial Officer. Mr. Ward is a certified public accountant, graduated summa cum laude from Long Island University, Brooklyn, NY. For most of the past fifteen years, Mr. Ward s experience has been in the generic pharmaceutical industry, most recently filling multiple finance and supply chain leadership roles with Actavis Group and its U.S. subsidiary, Amide Pharmaceuticals. Earlier in his career, he was the Chief Financial Officer for Positive Healthcare/Ceejay Healthcare, a U.S.Indian joint venture engaged in the manufacture and distribution of generic pharmaceuticals and nutraceuticals in India. Mr. Ward began his career in public accounting with KPMG.
  • Nasrat Hakim / Chairman
    • Mr. Hakim has more than years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, indepth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. From , Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing sites with more than , employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In , Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.Mr. Hakim s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs RAC from California State University at Sacramento, Sacramento, CA Bachelor in Chemistry/BioChemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.
  • David S. Caskey /
    • Davis Caskey brings more than years of pharmaceutical industry experience to this position. From until , Mr. Caskey was employed by ECR Pharmaceuticals ECR , a venture that was founded in and was acquired by HiTech Pharmacal Co., Inc. in March , where he served as the operating officer. Upon leaving ECR, Mr. Caskey formed Caskey LLC, an umbrella company to provide consulting services to the pharmaceutical industry and for the management of other business interests. While at ECR, Mr. Caskey was credited with the establishment of ECR s sales and marketing structure, its product distribution format, and management of the firm s internal organization. His responsibilities included the oversight of drug development and regulatory filings. A primary focus was to conceive and develop, with the assistance of key strategic partners, extended release formulations of products which enhance patient compliance and safety. Prior to ECR, Mr. Caskey was employed by A.H. Robins for years. His experience brings critical insight into the marketing and distribution of pharmaceutical products in a rapid and ever changing competitive marketplace. Mr. Caskey attended the University of Texas Austin and Lamar University, and holds bachelor s and master s degrees.
  • Barry Dash /
    • Dr. Barry Dash has served as a Director since April , a Member of the Audit Committee since April , a Member of the Nominating Committee since April and a Member of the Compensation Committee since June . Dr. Dash has been since President and Managing Member of Dash Associates, L.L.C., an independent consultant to the pharmaceutical and health industries. From to he was employed by American Home Products Corporation now known as Wyeth its WhitehallRobins Healthcare Division, initially as VP of Scientific Affairs, then Senior VP of Scientific Affairs and then Senior VP of Advanced Technologies during which time he personally supervised six separate departments: Medical and Clinical Affairs, Regulatory Affairs, Technical Affairs, Research and Development, Analytical R amp D and Quality Management/Q.C. Dr. Dash had been employed by the Whitehall Robins Healthcare Division from to , during which time he served as Director of Product Development Research, Assistant Vice President of Product Development and Vice President of Scientific Affairs. Dr. Dash had been employed by J.B. Williams Company Nabisco Brands, Inc. from to . From to he was Vice President, Director of Laboratories of the Consumer Products Division of American Can Company. He currently serves on the board of GeoPharma, Inc. NASDQ: GORX Dr. Dash holds a Ph.D. from the University of Florida and M.S. and B.S. degrees from Columbia University.
  • Eugene M. Pfeifer /
    • Eugene Pfeifer has served as a Director since April , . Mr. Pfeifer brings with him more than years of regulatory and trade experience, most recently having served as a law partner at King amp Spalding in Washington DC from to and prior to that as a law partner at the Burditt, Bowles amp Radzius from to . Among his many accomplishments, he was a major participant in the development of the Drug Price Competition and Patent Term Restoration Act of , and provided strategic counseling to companies affected by that statue. In addition, he has provided regulatory advice and representation on a wide variety of FDA, FTC, and DEA regulated activities, including product approval, advertising, promotion, and compliance issues. Prior to working at Burditt, Bowles and Radzius, Mr. Pfeifer served from to in the General Counsel s office of the Federal Trade Commission, where he represented the FTC in Federal Court to enjoin violations of the Federal Trade Commission Act, and served ten years in the Chief Counsel s Office at the FDA as Associated Chief Counsel for Enforcement, Associate Chief Counsel for Drugs and Deputy Chief Counsel for Regulations and Hearings. During his tenure at the FDA, he was the FDA s lead litigator and Appellate Court advocate, and he briefed the FDA s cases before the Supreme Court. Mr. Pfeifer is a graduate of Brown University and the Georgetown University Law Center.
  • Jeffrey Whitnell /
    • Jeffrey Whitnell has served as a Director since October , , Chairman of the Audit Committee since October , , member of the Compensation Committee since October , and designated by the Board as an audit committee financial expert . Since January , Mr. Whitnell has served as the Vice President, Finance amp Controller for LifeWatch Services. From June to March , Mr. Whitnell was the Chief Financial Officer for ReliefBand Medical Technologies, a medical device company. From June to June , Mr. Whitnell provided financial consulting services to various healthcare companies, including ReliefBand Medical Technologies. From June to June , Mr. Whitnell was Chief Financial Officer and Senior Vice President of Finance at Akorn, Inc. From June to June , Mr. Whitnell was Vice President of Finance and Treasurer for Ovation Pharmaceuticals. From to , Mr. Whitnell was Vice President of Finance and Treasurer for MediChem Research. Prior to , Mr. Whitnell held various finance positions at Akzo Nobel and Motorola. Mr. Whitnell began his career as an auditor with Arthur Andersen amp Co. He is a certified public accountant and holds an M.B.A. in Finance from the University of Chicago and a B.S. in Accounting from the University of Illinois. Mr. Whitnell s qualifications as an accounting and audit expert provide specific experience to serve as a director for the Company.

Current Share Structure

  • Market Cap: $83,789,982 - 03/09/2018
  • Authorized: 995,000,000 - 11/04/2016
  • Issue and Outstanding: 791,516,926 - 02/02/2018
  • Float: 766,363,798 - 06/15/2017

 


Recent Filings from (OTC: ELTP)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 31 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 19 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 09 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 09 2017
Filing Type: CT ORDERFiling Source: edgar
Filing Date: October, 11 2017

 

 


Daily Technical Chart for (OTC: ELTP)

Daily Technical Chart for (OTC: ELTP)


Stay tuned for daily updates and more on (OTC: ELTP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ELTP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ELTP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of ELTP and does not buy, sell, or trade any shares of ELTP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/